Stage 4 small-cell lung cancer: ongoing response to immunotherapy

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1-negative

Metastatic Site: liver, bone, brain

Extensive-stage small-cell lung cancer had complete response in the primary lung, liver, bone, and treated brain lesions, with partial response in hilar/mediastinal nodes; after about 20 months of serplulimab-based first-line therapy, the patient had no deterioration, no immunotherapy-related adverse effects, and high quality of life.

PubMed CentralRead more →

Stage 3C lung cancer: complete remission on immunotherapy and chemotherapy

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: EGFR wild-type; ALK rearrangement not detected; PD-L1 <1%

Complete tumor remission with no recurrence more than 6 months after durvalumab, tremelimumab, carboplatin, and nab-paclitaxel for Stage IIIC driver-negative NSCLC, despite severe immune, infectious, cardiac, renal, and fistula complications that later resolved or stabilized.

PubMed CentralRead more →

Stage IV Non-Small Cell Lung Cancer: Ashley's Survivor Story

Patient Info: Ashley Vasallo, Female, Under 40 | Stage IV

Biomarkers: No actionable driver biomarker identified; rare fusion reported

Metastatic Site: spine, hip/bone, chest cavity

As of October 2024, Ashley reported clear labs and scans after radiation for small chest-cavity and hip lesions, with scans planned every 3 months.

The Patient StoryRead more →

Stage III Lung Adenocarcinoma Treated With Complex Lung-Sparing Surgery and Adjuvant Therapy

Patient Info: Anonymized, male, Under 40 | Stage III

Biomarkers: PD-L1 high expression

Follow-up through 3 years after surgery showed no recurrence or metastasis, with stable lung function and unrestricted physical activity.

PubMed CentralRead more →

Two Severe Kidney Injuries After Lung Cancer Immunotherapy

Patient Info: Anonymized, Male, 70+

The lung cancer remained stable without further anticancer treatment, while the patient remained dependent on hemodialysis after the second kidney injury and continued tapering prednisolone.

PubMed CentralRead more →

Lung Cancer: Pascal's Survivor Story

Patient Info: Pascal, Male, 60s

As of the September 2024 article update, Pascal had resumed sports, felt well, and had been in complete remission for 26 months after an immunotherapy clinical trial following chemotherapy and radiation failure.

Stage IV Lung Cancer: Florence's Patient Story

Patient Info: Florence, Female, 40s | Stage IV

Metastatic Site: Brain

As of the September 2024 article update, Florence was living with metastatic lung cancer, traveling every 3 weeks for immunotherapy in a clinical trial, and reported less fatigue, more energy, and a return to sports and social life.

Stage 4 lung LCNEC: major response to chemotherapy plus immunotherapy

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: Large-cell neuroendocrine lung cancer markers were positive. PD-L1 was negative

Metastatic Site: left adrenal gland

By July 2024, PET-CT showed complete metabolic response of the adrenal metastasis, no visible adrenal disease, no pulmonary recurrence, and no distant metastasis after immunochemotherapy, lobectomy, adjuvant therapy, and serplulimab maintenance.

PubMed CentralRead more →

Stage 4 lung cancer: stable disease on immunotherapy combination

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: TP53, and MSH2 mutations; PD-L1 locally positive; Ki-67 20%; ALK negative. Markers otherwise supported lung cancer.

Metastatic Site: left atrium, right adrenal gland, skull; hilar and…

Stage IVB NSCLC remained clinically stable during carboplatin, pemetrexed, and tislelizumab, but treatment was stopped because of financial and psychological burden; later cancer status was not reported.

PubMed CentralRead more →

ALK-positive lung cancer spreading to both breasts after years of targeted therapy

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: ALK-positive, ALK mutation

Metastatic Site: bilateral breasts

At age 51, about 10 years after his Stage IV diagnosis, he remained alive with stable disease 8 months after removal of bilateral breast metastases while continuing maintenance therapy.

PubMed CentralRead more →

Pulmonary large cell neuroendocrine cancer treated with airway procedures and pembrolizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR negative, ALK negative, ROS1 negative, TP53 negative, PD-L1 <1%, TMB 28.3 mut/Mb

Metastatic Site: bilateral lungs

Pembrolizumab-based treatment produced a complete remission, but multiple intrapulmonary metastases recurred in October 2021 after an 18-month progression-free interval. Further local airway treatment was performed and pembrolizumab continued.

PubMed CentralRead more →

Stage 4 small-cell lung cancer: complete response on durvalumab

Patient Info: Anonymized, Female, 50s | Stage IV

Metastatic Site: pericardial effusion; left supraclavicular lymph node

As of July 2024, she had clinical complete response after chemoimmunotherapy and chest radiation, improving immune-related bone changes, and ongoing durvalumab maintenance every 4 weeks.

PubMed CentralRead more →

EGFR-mutant lung adenocarcinoma transforming to small cell lung cancer during targeted therapy

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion, TP53 mutation, TMB 11 mut/Mb

Metastatic Site: cervical lymph nodes

At the last follow-up in February 2024, 32 months after diagnosis, she was alive and both the primary lung lesion and cervical lymph-node metastasis had decreased on combined chemotherapy, immunotherapy and targeted therapy.

PubMed CentralRead more →

Stage 4 small cell lung cancer: response to carboplatin, etoposide, and atezolizumab

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: CD56-positive; synaptophysin-positive

Metastatic Site: right hilar/mediastinal disease, left adrenal gland,…

Extensive-stage small-cell lung cancer presenting with chronic intestinal pseudo-obstruction improved after 3 cycles of carboplatin, etoposide, and atezolizumab, with PET response and symptomatic improvement; longer-term durability was not reported.

PubMed CentralRead more →

Stage 4 lung cancer: immunotherapy plus particle therapy halts progression

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 90%; high tumor mutational burden; PIK3CA ; TP53 mutation; MET mutation

Metastatic Site: left proximal femur

Stage IV oligometastatic NSCLC had good CT response to carboplatin, pemetrexed, and pembrolizumab, then no disease progression 6 months after PULSAR radiotherapy plus pembrolizumab; grade 2 pneumonitis improved with prednisone.

PubMed CentralRead more →

Lung squamous cell carcinoma spreading to bone and intestine

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1 positive in almost all tumor cells

Metastatic Site: bone (left femur), intestine, abdomen

Despite chemotherapy, immunotherapy and radiation, the lung cancer progressed with intestinal and extensive abdominal metastases, cachexia and gastrointestinal bleeding. Palliative care was planned, but he chose discharge and received no further treatment.

PubMed CentralRead more →

Stage II Lung Cancer: Att's Patient Story

Patient Info: Att Callahan, Female, 70+ | Stage II

As of July 2024, Att was receiving monthly post-surgery immunotherapy and scans every other month after clinical-trial chemoimmunotherapy and lobectomy, with doctors believing they had removed all visible cancer.

MD AndersonRead more →

Stage IV PD-L1-negative lung adenocarcinoma: complete response with nivolumab and ipilimumab

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: PD-L1-negative; no targetable molecular alterations on DNA/RNA next-generation sequencing; TP53 alteration reported at 66%

Metastatic Site: left pleural effusion; right adrenal gland;…

As of February 2024, she remained on maintenance nivolumab and ipilimumab after 14 cycles, without significant toxicity and with persistent complete response of Stage IV PD-L1-negative lung adenocarcinoma.

PubMed CentralRead more →

Stage 4 lung cancer: complete response to chemo-immunotherapy combo

Patient Info: Anonymized, Male, 40s | Stage IV

Metastatic Site: right hilar lymph nodes, mediastinal lymph nodes

Stage IVA lung squamous cell carcinoma achieved complete response at 12 months. Pembrolizumab was stopped after immune-related RS3PE and likely colitis; 8 months after glucocorticoid initiation, there was no relapse of lung cancer or RS3PE.

PubMed CentralRead more →

Stage 3 lung cancer: complete response to chemo and immunotherapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Tumor markers were normal during mesorectal nodule workup; lung molecular biomarkers were not reported.

No radiologic NSCLC recurrence was detected during 16 months of follow-up after complete response to cisplatin/docetaxel chemoradiation plus 1 year of durvalumab; the suspicious mesorectal nodule proved to be a benign organized thrombus.

PubMed CentralRead more →

Stage IV lung squamous cell cancer complicated by adrenal insufficiency during immunotherapy

Patient Info: Anonymized, male, 50s | Stage IV

Mediastinal and hilar lymph nodes improved on treatment. Immunotherapy remained paused because of adrenal insufficiency, and updated follow-up found no recurrence or additional metastasis.

PubMed CentralRead more →

Stage IV lung squamous cell cancer with bone metastasis and immunotherapy-related adrenal insufficiency

Patient Info: Anonymized, male, 70+ | Stage IV

Metastatic Site: rib/bone

After earlier progression with rib/bone destruction, the latest chest CT showed lung lesions similar to prior imaging. Tislelizumab remained paused because of adrenal insufficiency.

PubMed CentralRead more →

Stage III lung squamous cell cancer treated with immunotherapy, surgery and chemotherapy

Patient Info: Anonymized, male, 50s | Stage III

After surgery and systemic treatment, updated follow-up found no recurrence or metastasis. Tislelizumab remained stopped after recurrent adrenal insufficiency.

PubMed CentralRead more →

Stage IV Non-Small Cell Lung Cancer: Lenny's Survivor Story

Patient Info: Lenny, Male, 50s | Stage IV

Biomarkers: PD-L1 expression positive

Metastatic Site: right femur; brain/cerebellum

As of July 2024, Lenny described himself as NED/no evidence of disease after surgery, CyberKnife radiation, chemotherapy, and Keytruda-based immunotherapy.

The Patient StoryRead more →